|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
|
|---|---|---|---|---|---|
| Cash Flows From Operating Activities | |||||
| Net income | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Depreciation and amortization | |||||
| Lease expense | |||||
| Deferred income taxes | |||||
| Share-based compensation | |||||
| Asbestos adjustments | |||||
| Excess tax benefits from share-based awards | |||||
| Gain on sale of land | |||||
| Non-cash restructuring expenses | |||||
| Non-cash interest expense | |||||
| Non-cash charge related to step up of inventory | |||||
| Other, net | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts and other receivables | |||||
| Inventories | |||||
| Operating lease assets and liabilities, net | |||||
| Prepaid expenses and other assets | |||||
| Insurance receivable - Asbestos | |||||
| Accounts payable and accrued liabilities | |||||
| Claims and handling costs paid - Asbestos | |||||
| Income taxes payable | |||||
| Other accrued liabilities and interest | |||||
| Net cash provided by operating activities | |||||
| Cash Flows From Investing Activities | |||||
| Purchases of property, plant and equipment | |||||
| Proceeds from sale of property, plant and equipment | |||||
| Capitalized interest | |||||
| Cash consideration for The AZEK Company acquisition, net of cash acquired | |||||
| Purchase of restricted investments - Asbestos | |||||
| Proceeds from restricted investments - Asbestos | |||||
| Net cash used in investing activities | |||||
| Cash Flows From Financing Activities | |||||
| Proceeds from term loans | |||||
| Proceeds from senior secured notes | |||||
| Proceeds from revolving credit facilities | |||||
| Repayments of term loans | |||||
| Repayments of revolving credit facilities | |||||
| Repayment of senior unsecured notes | |||||
| Debt issuance costs paid | |||||
| Proceeds from issuance of shares | |||||
| Proceeds from exercise of vested stock options | |||||
| Share issuance costs due to AZEK acquisition | |||||
| Repayment of finance lease obligations | |||||
| Shares repurchased | |||||
| Shares issued, net of cash paid for shares withheld for taxes | |||||
| Net cash provided by (used in) financing activities | |||||
| Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos | |||||
| Net (decrease) increase in cash and cash equivalents, restricted cash and restricted cash - Asbestos | |||||
| Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period | |||||
| Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period | |||||
| Non-Cash Investing and Financing Activities | |||||
| Capital expenditures incurred but not yet paid | |||||
| Non-cash ROU assets obtained in exchange for new lease liabilities | |||||
| Non-cash consideration for AZEK acquisition | |||||
| Supplemental Disclosure of Cash Flow Activities | |||||
| Cash paid for interest | |||||
| Cash payment for income taxes, net | |||||
| Cash paid to AICF | |||||
Loading...